Embed Size (px)
Citation preview
1
Fiscal Year 2018 5 April 2019
Dr. Andreas Eckert
CEO
2
Berlin
Medical Devices (RADIATION THERAPY)
Implantats
Applicators
Devices
Raw materials/
API
Projects/
API
Pharmaceuticals
(RADIOPHARMA)
Devices
Globally Positioned
Niche Player in Isotope Market
Industrial Components
(ISOTOPE PRODUCTS)
Products
Services
Trade
Disposal
In total 169 Mio. Euro revenues in 2018, incl. discontinued operations.
Based on preliminary figures, we expect in 2019 around 180 Mio. Euro revenues.
107 Mio. EUR
63%
30 Mio. EUR
18%
32 Mio. EUR
19%
Slides only for illustration – the spoken word shall be binding
800 Employees (Headcounts)
19 Sites Worldwide
3
Results 2018 (Mio. EUR)
Revenues 168,7
Net Income 16,1
47%
40%
10% 3%
EUROPE AMERICA ASIA MIDDLE EAST & AFRICA
Slides only for illustration – the spoken word shall be binding
Revenues Increase
by 24 Mio. EUR in 2018
in M
io. E
UR
4
incl. discontinued and continued operations
A total organic growth of 18%
0,13 1 2 4 6 6 8 10
24
33 31 29
36
42
50 54
71
101
111 116
120 117
127
140 138
145
169
0
20
40
60
80
100
120
140
160
180
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Slides only for illustration – the spoken word shall be binding
Revenues per Segment
2018 vs. 2017
5 Slides only for illustration – the spoken word shall be binding
Total Revenues of 168,7 Mio. EUR in 2018 vs. 145,0 Mio. EUR in 2017
incl. discontinued and continued operations
0
20
40
60
80
100
120
Isotope Products Radiation Therapy Radiopharma
2017 90 26 27
2018 107 30 32
In M
io. E
UR
Revenue Growth all Segments
in 2018, in Mio. EUR
6 Slides only for illustration – the spoken word shall be binding
144,8
+ 17,1
+ 4,5 + 4,9
70
90
110
130
150
170
190
Revenues 2017 Isotope Products Strahlentherapie Radiopharma Revenues 2018
168,7
Isotope Products Revenue
Growth 2018, in Mio. EUR
7 Slides only for illustration – the spoken word shall be binding
Acquisition
Gamma Group
High Demand in
Energy Sector
89,7
+ 13,9 - 3,5 + 6,7
106,8
20
30
40
50
60
70
80
90
100
110
120
Revenues 2017 Organic Growth Exchange Rate Effects M&A and Divesture Revenues 2018
Radiopharma Revenue Growth
2018, in Mio. EUR
8 Slides only for illustration – the spoken word shall be binding
Zyklotron
Divesture
Pharmaceutical
Radioisotope
26,6
+ 11,7
- 0,5
- 6,2
31,6
5
10
15
20
25
30
35
40
Revenues 2017 Organic Growtth Exchange Rate Effects M&A and Divesture Revenues 2018
25,9
+ 2,6 - 0,4
+ 2,2
30,4
12
14
16
18
20
22
24
26
28
30
32
Revenues 2017 Organic Growth Exchange Rate Effects M&A and Divesture Revenues 2018
Radiation Therapy Revenue
Growth 2018, in Mio. EUR
9 Slides only for illustration – the spoken word shall be binding
Acquisition
WOMED
HDR Sales
10 Slides only for illustration – the spoken word shall be binding
Fiscal Year 2018
Net Income – Distribution and Growth
Net Income in 2018 vs. 2017
in Mio. EUR
11
Total Net Income of 16,1 Mio. EUR in 2018 vs. 14,7 Mio. in 2018
0,0
2,0
4,0
6,0
8,0
10,0
12,0
Isotope Products Radiation Therapy Radiopharma
2017 6,9 0,9 4,4
2018 11,6 0,7 6,4
In M
io. E
UR
Slides only for illustration – the spoken word shall be binding
Net Income Distribution
by Segment, 2018
12
62%
4%
34%
Isotope Products
Radiation Therapy
Radiopharma
16,1 Mio. EUR Net Income
2018
Isotope
Products
Radio-
pharma
Radiation
Therapy
11,6 6,4 0,7
Split in Mio. EUR without Holding
Slides only for illustration – the spoken word shall be binding
Revenue Distribution by
Segment, 2018
13 Slides only for illustration – the spoken word shall be binding
63%
18%
19%
Isotope Products
Radiation Therapy
Radiopharma
168,7 Mio. EUR Revenues
2018
Isotope
Products
Radio-
pharma
Radiation
Therapy
106,8 31,6 30,4
Split in Mio. EUR without Holding
Net Income Growth all
Segments in 2018, in Mio. EUR
14 Slides only for illustration – the spoken word shall be binding
14,7
+ 4,7
- 0,2 + 2,0 - 2,0
16,1
0,0
5,0
10,0
15,0
20,0
25,0
Net Income 2017 Isotope Products Radiation Therapy Radiopharma Holding Net Income 2018
15 Slides only for illustration – the spoken word shall be binding
Fiscal Year 2018
Cashflow and Balance Sheet
Balance Sheet in 2018
in Mio. EUR
16
• Cash at Hand 54 Mio. EUR
• Debt Free
• Equity Ratio 54%
Slides only for illustration – the spoken word shall be binding
Cash 54 Equity 124
Recievables 28 Minority Interests 0
Inventory 29 Loans 0
Intangible Assets 53 Accruals/Provisions 65
Fixed Assets 37 Other Short Term Payables 34
Others 28 Other Long Term Payables 6
Total Activ 229 Total Passiv 229
57,7
21,1
-8,2
-16,9
0,6
54,2
30,0
40,0
50,0
60,0
70,0
80,0
90,0
Cash at 31.12.2017 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Cash at 31.12.2018
Cashflow in 2018
in Mio. EUR
17
Own Share
Acquisition in
Merger Process,
Dividends
Slides only for illustration – the spoken word shall be binding
EBITDA: 31,7 Mio. EUR
18 Slides only for illustration – the spoken word shall be binding
5 YEAR PERSPECTIVE
19
Mergers and Acquisitions,
Cooperations
• 2014
– Acquisition of Brazilian Isotope Specialist REM
– Accreditation Gallium Generator/ API
– New Projects & Business Activities in Therapy Segment
• 2015 – Sale of US-Seed Business to Theragenics
– Closing of Oxford/ (US)
– Closing of French Sales Accessories Unit
– Lucrative Sales of OPS to IPSEN
• 2016 – Acquisition of Belgian Brachytherapie Unit
– Acquisition of Brazilian Transports Specialist
– Cooperation Contract with CURASIGHT
– FDA-Approval for NETSPOT/ (API of EZAG)
• 2017 – Sale of Zyklotron Business to Alliance Medical
– Acquisition of Gamma-Service Group, Leipzig
• 2018 Acquisition of WOMED
Merger BEBIG S.A. und EZAG AG
Slides only for illustration – the spoken word shall be binding
Profitability (Net Income/ EPS)
Initially Planned to Oscilate
6,8
10,7
9,6
14,7
10,9
1,28 €
2,03 € 1,81 €
2,78 €
2,06 €
5,0
7,0
9,0
11,0
13,0
15,0
0,50
1,00
1,50
2,00
2,50
3,00
2014 2015 2016 2017 2018 Budget
Mio. EUR EUR/Aktie
20 Slides only for illustration – the spoken word shall be binding
Basis: 5,3 Mio. shares
Profitability (Net Income/ EPS)
Now Set for Straight Increase
6,8
10,7
9,6
14,7
16,1
1,28 €
2,03 €1,81 €
2,78 €
3,12 €
0,0
2,0
4,0
6,0
8,0
10,0
12,0
14,0
16,0
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
2014 2015 2016 2017 2018
Mio. EUR EUR/Aktie
21 Slides only for illustration – the spoken word shall be binding
„Verdauung“
Industry
& RI
Basis: 5,2 Mio. shares
Stock and Dividend,
In EUR/Stock
22 Slides only for illustration – the spoken word shall be binding
0,60 0,60 0,600,66
0,8
1,2
0,50
0,60
0,70
0,80
0,90
1,00
1,10
1,20
0
10
20
30
40
50
60
70
80
90
100
2014 2015 2016 2017 2018 2019
Dividende in EUR / Aktie EUR/Aktie
5 Years Cashflow Outlook,
in Mio. EUR
23
2014 2015 2016 2017 2018
Zahlungsmittel 22 31 37 58 54
Darlehen 19 16 12 2 0
Nettoliquidität 3 15 25 56 54
0
10
20
30
40
50
60
0
10
20
30
40
50
60
In M
io. E
UR
Slides only for illustration – the spoken word shall be binding
+10 mm EUR for
treasury shares
Financial Calendar / IR-Contact
IR-Kontakt
Eckert & Ziegler AG
Karolin Riehle
Investor Relations & PR
Robert-Rössle-Str. 10
D-13125 Berlin
Tel. +49 30 94 10 84-138
Fax +49 30 94 10 84-112
www.ezag.de
ISIN DE0005659700
Reuters EUZ.DE
24 Slides only for illustration – the spoken word shall be binding
05.04.2019 Figures FY 2018
07.05.2019 Quarterly Report I
15.05.2019 Spring Conference in Frankfurt
29.05.2019 Annual General Meeting in Berlin
13.08.2019 Quarterly Report II
12.11.2019 Quarterly Report III
Nov. 2019 German Equity Forum in Frankfurt
Thank you for your attention!
Slides only for illustration – the spoken word shall be binding 25
